Amar Thyagarajan, PhD

Graphio stops revenue loss before it happens by detecting broken handoffs between teams. We analyze API-enabled metadata from your existing systems to automatically identify when Sales, CS, Legal, Finance, Product, and Operations are misaligned before deals stall, renewals fail, or contracts slip. Technically, It’s a Context-Change Graph AI that learns your companys blueprint for success. It tracks live performance against that map to predict, alert, and repair dangerous deviations the moment they happen Zero integrations. Zero workflow disruption. Privacy by design: we dont analyze your content - only metadata. Launch in under 48 hours. SOC 2 Type 2, HIPAA compliant.

Graphio stops revenue loss before it happens by detecting broken handoffs between teams. We analyze API-enabled metadata from your existing systems to automatically identify when Sales, CS, Legal, Finance, Product, and Operations are misaligned before deals stall, renewals fail, or contracts slip. Technically, It’s a Context-Change Graph AI that learns your companys blueprint for success. It tracks live performance against that map to predict, alert, and repair dangerous deviations the moment they happen Zero integrations. Zero workflow disruption. Privacy by design: we dont analyze your content - only metadata. Launch in under 48 hours. SOC 2 Type 2, HIPAA compliant.

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit www.crownbio.com.